Cochrane · systematic review · CD004289
HMG CoA reductase inhibitors (statins) for dialysis patients
Palmer, SC, Navaneethan, SD, Craig, JC, et al. · Cochrane Database of Systematic Reviews · 2013 · Cochrane Library
Kidney and TransplantAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
3
current version
GRADE rated
3
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 2 · 66.7%High 1 · 33.3%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Comparison
Population: adults with chronic kidney disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Major cardiovascular events | RR 0.95 [0.88, 1.03] | 4 studies · 7804 participants | High |
All‐cause mortality | RR 0.96 [0.9, 1.02] | 13 studies · 4705 participants | Moderate |
Cardiovascular mortality | RR 0.94 [0.84, 1.06] | 13 studies · 4627 participants | Moderate |